Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance Program
- 1 August 2008
- journal article
- Published by Springer Science and Business Media LLC in Pediatric Research
- Vol. 64 (2), 200-204
- https://doi.org/10.1203/pdr.0b013e318179954c
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Epoprostenol treatment in children with severe pulmonary hypertensionHeart, 2007
- Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinilEuropean Respiratory Journal, 2006
- Outcomes in Children With Idiopathic Pulmonary Arterial HypertensionCirculation, 2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJournal of the American College of Cardiology, 2004
- Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial HypertensionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Pulmonary arterial hypertension in childrenEuropean Respiratory Journal, 2003
- Bosentan Therapy for Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Vasodilator Therapy for Primary Pulmonary Hypertension in ChildrenCirculation, 1999
- Primary Pulmonary HypertensionThe New England Journal of Medicine, 1997